目感染症治療の世界市場2020年-2030年

◆英語タイトル:Eye Infections Treatment Market - Global Industry Analysis and Opportunity Assessment, 2020-2030
◆商品コード:FMI20JL041
◆発行会社(リサーチ会社):Future Market Insights
◆発行日:2020年5月11日
◆ページ数:256
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Individual Price(1名様閲覧用)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Corporate Price(同一法人内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Future Market Insights社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、目感染症治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概要、市場背景、需要分析及び予測、価格分析、薬物種類別(スルホンアミド、マクロライド、エリスロマイシン、クロラムフェニコール、アミノグリコシド)分析、剤形別分析、疾患別分析、原因物質別分析、流通経路別分析、地域別分析などの構成でお届けいたします。
・エグゼクティブサマリー
・市場概要
・キートレンド
・市場背景
・市場状況
・新型コロナウイルス危険分析
・需要分析及び予測
・目感染症治療の世界市場:薬物種類別(スルホンアミド、マクロライド、エリスロマイシン、クロラムフェニコール、アミノグリコシド)
・目感染症治療の世界市場:剤形別
・目感染症治療の世界市場:疾患別
・目感染症治療の世界市場:原因物質別
・目感染症治療の世界市場:流通経路別
・目感染症治療の世界市場:地域別
【レポートの概要】

A recent market study published by Future Market Insights on the eye infection treatment market includes global industry analysis for 2015-2019 & opportunity assessment for 2020-2030, and delivers a comprehensive assessment of the most important market dynamics and Covid-19 crisis impact analysis. After conducting a thorough research on the historical as well as current growth parameters of the market, the growth prospects of the market are obtained with maximum precision.

EYE INFECTIONS TREATMENT MARKET TAXONOMY
The global eye infection treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug Class
Antibiotics
Antivirals
Antifungals
Antihistamines
Corticosteroids
Glucocorticoids

Dosage Form
Tablet
Capsule
Ophthalmic Ointment
Eye Drops
Others

Indications
Conjunctivitis
Keratitis
Endophthalmitis
Blepharitis
Stye or Sty (Hordeolum)
Uveitis
Cellulitis
Ocular herpes

Causative Agents
Virus
Bacteria
Fungus
Allergens

Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

Regions
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

WHAT’S INCLUDED
Chapter 01 – Executive Summary
The report initiates with the executive summary of the eye infection treatment market, which includes a summary of key findings and statistics of the market. It also includes supply-side and demand-side trends pertaining to the market.

Chapter 02 – Market Overview
Readers can find the definition and a detailed segmentation of the market in this chapter, which will help them understand the basic information about the market. Along with this, comprehensive information pertaining to types of products and their features are provided in this section. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the market report.

Chapter 03 – Key Market Trends
Eye infection treatment market report provides the key market trends that are expected to significantly impact market growth during the forecast period. Detailed industry trends are provided in this section.

Chapter 04 – Key Success Factor
This section includes the key successful factors and strategies being adopted by key market participants.

Chapter 05 – Global Market Value Analysis 2015-2019 & Opportunity Assessment 2020-2030
This section explains the global market value analysis and forecast for the market during the forecast period. This chapter includes a detailed analysis of the historical market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2020-2030).

Chapter 06 – Market Dynamics
This chapter gives information about COVID-19 crisis impact analysis which comprises of current covid19 statistics and probable future impact, impact on GDP of individual key countries, segment wise impact, quarter-wise forecast and projected recovery quarter. In addition, this chapter includes drivers and restraints of the market. This section also includes macroeconomic factors and various opportunities of the market.

Chapter 07 – Global Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Drug Class
Based on drug class, the market is segmented into antibiotics, antivirals, antifungals, antihistamines, corticosteroids, and glucocorticoids. In this chapter, readers can find information about Y-o-Y growth and market attractiveness analysis based on drug class.

Chapter 08 – Global Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Dosage Form
Based on dosage form, the market is segmented into tablet, capsule, ophthalmic ointment, and eye drops. In this chapter, readers can find information about Y-o-Y growth and market attractiveness analysis based on dosage form.

Chapter 09 – Global Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Indication
Based on indication, the market is segmented into conjunctivitis, keratitis, endophthalmitis, blepharitis, stye or sty (hordeolum), uveitis, cellulitis, and ocular herpes. In this chapter, readers can find information about Y-o-Y growth and market attractiveness analysis based on indication.

Chapter 10 – Global Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Causative Agents
Based on causative agents, the market is segmented into virus, bacteria, fungus, and allergens. In this chapter, readers can find information about Y-o-Y growth and market attractiveness analysis based on causative agents.

Chapter 11 – Global Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Distribution Channel
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. In this chapter, readers can find information about Y-o-Y growth and market attractiveness analysis based on distribution channel.

Chapter 12 – Global Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Region
This chapter explains how the eye infection treatment market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia & Oceania, and Middle East & Africa (MEA).

Chapter 13 – North America Market Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter includes a detailed analysis of growth of the North America market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, and market growth based on the drug class, dosage form, indication, causative agent, distribution channel, and countries in North America.

Chapter 14 – Latin America Market Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter provides the growth scenario of the market in Latin American countries such as Brazil, Mexico, Argentina and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.

Chapter 15 – Europe Market Analysis 2015-2019 & Opportunity Assessment 2020-2030
Important growth prospects of the market based on its end users in several countries such as the U.K., France, Germany, Spain, Italy, Russia and the Rest of Europe are included in this chapter.

Chapter 16 – East Asia Market Analysis 2015-2019 & Opportunity Assessment 2020-2030
Important growth prospects of the eye infection treatment market across target segments in several countries such as China, Japan and South Korea are included in this chapter.

Chapter 17 – South Asia Market Analysis 2015-2019 & Opportunity Assessment 2020-2030
In this chapter, India and Indonesia countries are the prominent countries in the South Asia region. Readers can find detailed information about the growth parameters of the South Asia market during the forecast period of 2020-2030.

Chapter 18 – Oceania Market Analysis 2015-2019 & Opportunity Assessment 2020-2030
In this chapter, Australia and New Zealand are the prominent countries in the Oceania region. Readers can find detailed information about the growth parameters of the South Asia market during the forecast period of 2020-2030.

Chapter 19 – MEA Market Analysis 2015-2019 & Opportunity Assessment 2020-2030
This chapter provides information about how the eye infection treatment market will grow in major countries in the MEA region such as GCC Countries, South Africa, and the Rest of MEA, during the forecast period of 2020-2030.

Chapter 20 – Market Structure Analysis
This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key player operating in market.

Chapter 21 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured are Pfizer Inc. (U. S.), Allergan Plc. (Ireland), Alcon Laboratories, Inc. (Switzerland), Akron Pharma Inc. (U. S.), Bausch Health Companies Inc. (Canada), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (U. S.), Aurobindo Pharma (India), Lupin Limited (India), and Eyevance Pharmaceuticals LLC (U. S.).

Chapter 22 – Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the eye infection treatment market report.

Chapter 23 – Research Methodology
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the eye infection treatment market.

【レポートの目次】

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Technology Roadmap

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Development Trends

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global GDP Growth Outlook

4.1.2. Global Healthcare Spending Outlook

4.2. Forecast Factors – Relevance & Impact

4.2.1. Adoption of Drugs

4.2.2. Disease Prevalence

4.2.3. Reimbursement scenario

4.2.4. Regulatory Scenario

4.2.5. Product in Pipeline

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity Analysis

5. Market Context

5.1. Drug Type vs Indication Analysis

5.2. Strategic Promotional Analysis, By Key Manufacturers

5.3. Key Regulations

5.4. Porter’s Five Forces Analysis

5.5. PESTLE Analysis

6. COVID19 Crisis Analysis

6.1. Current COVID19 Statistics and Probable Future Impact

6.2. Current GDP Projection and Probable Impact

6.3. Current Economic Projection as compared to 2008 financial analysis

6.4. COVID19 and Impact Analysis

6.4.1. Revenue By Product

6.4.2. Revenue By Dosage Form

6.4.3. Revenue By Country

6.5. 2020 Market Scenario

6.6. Quarter by Quarter Forecast

6.7. Projected recovery Quarter

6.8. Recovery Scenario – Short term, Midterm and Long Term Impact Global

7. Global Eye Infection treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

7.2.1. Y-o-Y Growth Trend Analysis

8. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015 – 2019

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2020 – 2030

8.3.1. Antibiotics

8.3.1.1. Sulfonamides

8.3.1.2. Macrolides

8.3.1.3. Erythromycin

8.3.1.4. Chloramphenicol

8.3.1.5. Aminoglycosides

8.3.1.6. Fluoroquinolones

8.3.1.7. Vancomycin

8.3.1.8. Tetracyclines

8.3.2. Antivirals

8.3.2.1. Thymidine-Based Nucleoside Analogues (Trifluridine)

8.3.2.2. Thymidine Phosphorylase Inhibitors (Trifluridine)

8.3.2.3. Acyclic Nucleoside Analogue of 2′Deoxyguanasine (Ganciclovir)

8.3.2.4. Acyclic Guanine Nucleoside Analog (Acyclovir)

8.3.2.5. Others

8.3.3. Antifungals

8.3.3.1. Polyenes (Amphotericin B (AMB) And Natamycin (NTM))

8.3.3.2. Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))

8.3.3.3. Pyrimidines

8.3.3.4. Echinocandins (Caspofungin (CFG) and Micafungin (MFG))

8.3.3.5. Others

8.3.4. Antihistamines

8.3.5. Corticosteroids

8.3.6. Glucocorticoids

8.4. Market Attractiveness Analysis By Drug Class

9. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Dosage Form

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) Analysis By Dosage Form, 2015 – 2019

9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Dosage Form, 2020 – 2030

9.3.1. Tablet

9.3.2. Capsule

9.3.3. Ophthalmic Ointment

9.3.4. Eye Drops

9.3.5. Others

9.4. Market Attractiveness Analysis By Dosage Form

10. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Indication

10.1.Introduction / Key Findings

10.2.Historical Market Size (US$ Mn) Analysis By Indication, 2015 – 2019

10.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020 – 2030

10.3.1. Conjunctivitis

10.3.2. Keratitis

10.3.3. Endophthalmitis

10.3.4. Blepharitis

10.3.5. Stye or Sty (Hordeolum)

10.3.6. Uveitis

10.3.7. Cellulitis

10.3.8. Ocular herpes

10.4.Market Attractiveness Analysis By Indication

11. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Causative Agent

11.1.Introduction / Key Findings

11.2.Historical Market Size (US$ Mn) Analysis By Causative Agent, 2015 – 2019

11.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Causative Agent, 2020 – 2030

11.3.1. Virus

11.3.2. Bacteria

11.3.3. Fungus

11.3.4. Allergens

11.4.Market Attractiveness Analysis By Causative Agent

12. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel

12.1.Introduction / Key Findings

12.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 – 2019

12.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 – 2030

12.3.1. Hospital Pharmacy

12.3.2. Retail Pharmacy

12.3.3. Drug Stores

12.3.4. Online Pharmacy

12.4.Market Attractiveness Analysis By Distribution Channel

13. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region

13.1.Introduction

13.2.Historical Market Size (US$ Mn) Analysis By Region, 2015 – 2019

13.3.Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020 – 2030

13.3.1. North America

13.3.2. Latin America

13.3.3. Europe

13.3.4. South Asia

13.3.5. East Asia

13.3.6. Oceania

13.3.7. Middle East and Africa (MEA)

13.4.Market Attractiveness Analysis By Region

14. North America Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

14.1. Introduction

14.2. Pricing Analysis

14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2020 – 2030

14.4.1. By Country

14.4.1.1. U.S.

14.4.1.2. Canada

14.4.2. By Drug Class

14.4.3. By Dosage Form

14.4.4. By Indications

14.4.5. By Causative Agent

14.4.6. By Distribution Channel

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Drug Class

14.5.3. By Dosage Form

14.5.4. By Indications

14.5.5. By Causative Agent

14.5.6. By Distribution Channel

14.6. Market Trends

14.7. Key Market Participants – Intensity Mapping

14.8. Drivers and Restraints – Impact Analysis

15. Latin America Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

15.1. Introduction

15.2. Pricing Analysis

15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2020 – 2030

15.4.1. By Country

15.4.1.1. Brazil

15.4.1.2. Mexico

15.4.1.3. Rest of Latin America

15.4.2. By Drug Class

15.4.3. By Dosage Form

15.4.4. By Indications

15.4.5. By Causative Agent

15.4.6. By Distribution Channel

15.5. Market Attractiveness Analysis

15.5.1. By Country

15.5.2. By Drug Class

15.5.3. By Dosage Form

15.5.4. By Indications

15.5.5. By Causative Agent

15.5.6. By Distribution Channel

15.6. Market Trends

15.7. Key Market Participants – Intensity Mapping

15.8. Drivers and Restraints – Impact Analysis

16. Europe Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

16.1. Introduction

16.2. Pricing Analysis

16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

16.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

16.4.1. By Country

16.4.1.1. Germany

16.4.1.2. U.K.

16.4.1.3. France

16.4.1.4. France

16.4.1.5. Italy

16.4.1.6. Spain

16.4.1.7. Russia

16.4.1.8. Rest of Europe

16.4.2. By Drug Class

16.4.3. By Dosage Form

16.4.4. By Indications

16.4.5. By Causative Agent

16.4.6. By Distribution Channel

16.5. Market Attractiveness Analysis

16.5.1. By Country

16.5.2. By Drug Class

16.5.3. By Dosage Form

16.5.4. By Indications

16.5.5. By Causative Agent

16.5.6. By Distribution Channel

16.6. Market Trends

16.7. Key Market Participants – Intensity Mapping

16.8. Drivers and Restraints – Impact Analysis

17. South Asia Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

17.1. Introduction

17.2. Pricing Analysis

17.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 – 2019

17.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

17.4.1. By Country

17.4.1.1. India

17.4.1.2. Thailand

17.4.1.3. Indonesia

17.4.1.4. Malaysia

17.4.1.5. Rest of South Asia

17.4.2. By Drug Class

17.4.3. By Dosage Form

17.4.4. By Indications

17.4.5. By Causative Agent

17.4.6. By Distribution Channel

17.5.Market Attractiveness Analysis

17.5.1. By Country

17.5.2. By Drug Class

17.5.3. By Dosage Form

17.5.4. By Indications

17.5.5. By Causative Agent

17.5.6. By Distribution Channel

17.6.Market Trends

17.7.Key Market Participants – Intensity Mapping

17.8.Drivers and Restraints – Impact Analysis

18. East Asia Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

18.1. Introduction

18.2. Pricing Analysis

18.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 – 2019

18.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

18.4.1. By Country

18.4.1.1. China

18.4.1.2. Japan

18.4.1.3. South Korea

18.4.2. By Drug Class

18.4.3. By Dosage Form

18.4.4. By Indications

18.4.5. By Causative Agent

18.4.6. By Distribution Channel

18.5.Market Attractiveness Analysis

18.5.1. By Country

18.5.2. By Drug Class

18.5.3. By Dosage Form

18.5.4. By Indications

18.5.5. By Causative Agent

18.5.6. By Distribution Channel

18.6 .Market Trends

18.7. Key Market Participants – Intensity Mapping

18.8. Drivers and Restraints – Impact Analysis

19. Oceania Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

19.1.Introduction

19.2.Pricing Analysis

19.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

19.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

19.4.1. By Country

19.4.1.1. Australia

19.4.1.2. New Zealand

19.4.2. By Drug Class

19.4.3. By Dosage Form

19.4.4. By Indications

19.4.5. By Causative Agent

19.4.6. By Distribution Channel

19.5.Market Attractiveness Analysis

19.5.1. By Country

19.5.2. By Drug Class

19.5.3. By Dosage Form

19.5.4. By Indications

19.5.5. By Causative Agent

19.5.6. By Distribution Channel

19.6.Market Trends

19.7.Key Market Participants – Intensity Mapping

19.8.Drivers and Restraints – Impact Analysis

20. Middle East and Africa Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

20.1.Introduction

20.2.Pricing Analysis

20.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

20.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

20.4.1. By Country

20.4.1.1. GCC Countries

20.4.1.2. Turkey

20.4.1.3. Northern Africa

20.4.1.4. South Africa

20.4.1.5. Rest of Middle East and Africa

20.4.2. By Drug Class

20.4.3. By Dosage Form

20.4.4. By Indications

20.4.5. By Causative Agent

20.4.6. By Distribution Channel

20.5.Market Attractiveness Analysis

20.5.1. By Country

20.5.2. By Drug Class

20.5.3. By Dosage Form

20.5.4. By Indications

20.5.5. By Causative Agent

20.5.6. By Distribution Channel

20.6.Market Trends

20.7.Key Market Participants – Intensity Mapping

20.8.Drivers and Restraints – Impact Analysis

21. Emerging Countries Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

21.1.Introduction

21.1.1. Market Value Proportion Analysis, By Key Countries

21.1.2. Global Vs. Country Growth Comparison

21.2.China Eye Infection treatment Market Analysis

21.2.1. Introduction

21.2.2. Pricing Analysis

21.2.3. PEST Analysis

21.2.4. Market Value Proportion Analysis by Market Taxonomy

21.2.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

21.2.5.1. By Drug Class

21.2.5.2. By Dosage Form

21.2.5.3. By Indications

21.2.5.4. By Causative Agent

21.2.5.5. By Distribution Channel

21.2.6. China Eye Infection treatment Market – Competition Landscape

21.2.7. China – Trade Analysis

21.3.India Eye Infection treatment Market Analysis

21.3.1. Introduction

21.3.2. Pricing Analysis

21.3.3. PEST Analysis

21.3.4. Market Value Proportion Analysis by Market Taxonomy

21.3.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

21.3.5.1. By Drug Class

21.3.5.2. By Dosage Form

21.3.5.3. By Indications

21.3.5.4. By Causative Agent

21.3.5.5. By Distribution Channel

21.3.6. India Eye Infection treatment Market – Competition Landscape

21.4.Brazil Eye Infection treatment Market Analysis

21.4.1. Introduction

21.4.2. Pricing Analysis

21.4.3. PEST Analysis

21.4.4. Market Value Proportion Analysis by Market Taxonomy

21.4.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

21.4.5.1. By Drug Class

21.4.5.2. By Dosage Form

21.4.5.3. By Indications

21.4.5.4. By Causative Agent

21.4.5.5. By Distribution Channel

21.4.6. Brazil Eye Infection treatment Market – Competition Landscape

22. Market Structure Analysis

22.1.Market Analysis by Tier of Companies (Eye Infection treatment)

22.2.Market Concentration

22.3.Market Share Analysis of Top Players

22.4.Market Presence Analysis

22.4.1. By Regional footprint of Players

22.4.2. Product foot print by Players

22.4.3. Channel Foot Print by Players

23. Competition Analysis

23.1.Competition Dashboard

23.2.Pricing Analysis by Competition

23.3.Competition Benchmarking

23.4.Competition Deep Dive

23.4.1. Allergan plc

23.4.1.1. Overview

23.4.1.2. Product Portfolio

23.4.1.3. Profitability by Market Segments (Product/Channel/Region)

23.4.1.4. Sales Footprint

23.4.1.5. Strategy Overview

23.4.1.5.1. Marketing Strategy

23.4.1.5.2. Product Strategy

23.4.1.5.3. Channel Strategy

23.4.2. Alcon Laboratories, Inc.

23.4.2.1. Overview

23.4.2.2. Product Portfolio

23.4.2.3. Profitability by Market Segments (Product/Channel/Region)

23.4.2.4. Sales Footprint

23.4.2.5. Strategy Overview

23.4.2.5.1. Marketing Strategy

23.4.2.5.2. Product Strategy

23.4.2.5.3. Channel Strategy

23.4.3. Bausch Health Companies Inc.

23.4.3.1. Overview

23.4.3.2. Product Portfolio

23.4.3.3. Profitability by Market Segments (Product/Channel/Region)

23.4.3.4. Sales Footprint

23.4.3.5. Strategy Overview

23.4.3.5.1. Marketing Strategy

23.4.3.5.2. Product Strategy

23.4.3.5.3. Channel Strategy

23.4.4. Pfizer Inc.

23.4.4.1. Overview

23.4.4.2. Product Portfolio

23.4.4.3. Profitability by Market Segments (Product/Channel/Region)

23.4.4.4. Sales Footprint

23.4.4.5. Strategy Overview

23.4.4.5.1. Marketing Strategy

23.4.4.5.2. Product Strategy

23.4.4.5.3. Channel Strategy

23.4.5. Akron Pharma Inc.

23.4.5.1. Overview

23.4.5.2. Product Portfolio

23.4.5.3. Profitability by Market Segments (Product/Channel/Region)

23.4.5.4. Sales Footprint

23.4.5.5. Strategy Overview

23.4.5.5.1. Marketing Strategy

23.4.5.5.2. Product Strategy

23.4.5.5.3. Channel Strategy

23.4.6. Sanofi S.A.

23.4.6.1. Overview

23.4.6.2. Product Portfolio

23.4.6.3. Profitability by Market Segments (Product/Channel/Region)

23.4.6.4. Sales Footprint

23.4.6.5. Strategy Overview

23.4.6.5.1. Marketing Strategy

23.4.6.5.2. Product Strategy

23.4.6.5.3. Channel Strategy

23.4.7. GlaxoSmithKline plc

23.4.7.1. Overview

23.4.7.2. Product Portfolio

23.4.7.3. Profitability by Market Segments (Product/Channel/Region)

23.4.7.4. Sales Footprint

23.4.7.5. Strategy Overview

23.4.7.5.1. Marketing Strategy

23.4.7.5.2. Product Strategy

23.4.7.5.3. Channel Strategy

23.4.8. Intas Pharmaceuticals Ltd

23.4.8.1. Overview

23.4.8.2. Product Portfolio

23.4.8.3. Profitability by Market Segments (Product/Channel/Region)

23.4.8.4. Sales Footprint

23.4.8.5. Strategy Overview

23.4.8.5.1. Marketing Strategy

23.4.8.5.2. Product Strategy

23.4.8.5.3. Channel Strategy

23.4.9. Johnson & Johnson Services, Inc.

23.4.9.1. Overview

23.4.9.2. Product Portfolio

23.4.9.3. Profitability by Market Segments (Product/Channel/Region)

23.4.9.4. Sales Footprint

23.4.9.5. Strategy Overview

23.4.9.5.1. Marketing Strategy

23.4.9.5.2. Product Strategy

23.4.9.5.3. Channel Strategy

23.4.10. Macleods Pharmaceuticals Ltd.

23.4.10.1. Overview

23.4.10.2. Product Portfolio

23.4.10.3. Profitability by Market Segments (Product/Channel/Region)

23.4.10.4. Sales Footprint

23.4.10.5. Strategy Overview

23.4.10.5.1. Marketing Strategy

23.4.10.5.2. Product Strategy

23.4.10.5.3. Channel Strategy

23.4.11. Merck & Co., Inc.

23.4.11.1. Overview

23.4.11.2. Product Portfolio

23.4.11.3. Profitability by Market Segments (Product/Channel/Region)

23.4.11.4. Sales Footprint

23.4.11.5. Strategy Overview

23.4.11.5.1. Marketing Strategy

23.4.11.5.2. Product Strategy

23.4.11.5.3. Channel Strategy

23.4.12. Mylan N.V.

23.4.12.1. Overview

23.4.12.2. Product Portfolio

23.4.12.3. Profitability by Market Segments (Product/Channel/Region)

23.4.12.4. Sales Footprint

23.4.12.5. Strategy Overview

23.4.12.5.1. Marketing Strategy

23.4.12.5.2. Product Strategy

23.4.12.5.3. Channel Strategy

23.4.13. Teva Pharmaceutical Industries Ltd.

23.4.13.1. Overview

23.4.13.2. Product Portfolio

23.4.13.3. Profitability by Market Segments (Product/Channel/Region)

23.4.13.4. Sales Footprint

23.4.13.5. Strategy Overview

23.4.13.5.1. Marketing Strategy

23.4.13.5.2. Product Strategy

23.4.13.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[目感染症治療の世界市場2020年-2030年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆